Literature DB >> 1530823

Reversed vein graft stenosis: early diagnosis and management.

H D Berkowitz1, A D Fox, D H Deaton.   

Abstract

Conscientious surveillance of intrainguinal bypass grafts is mandatory to detect vein graft stenoses, which, if uncorrected, can lead to graft occlusion. It is now widely accepted that noninvasive vascular laboratory studies are the best way to detect these lesions. However, controversy still exists over treatment, specifically whether balloon angioplasty is an acceptable substitute for surgery (patch angioplasty or short jump grafts) in the treatment of these lesions. We have always favored balloon angioplasty as primary treatment and have summarized our experience with treating 72 stenotic reversed femoropopliteal and femorotibial vein grafts, which represent 12% of 521 bypass grafts performed at our institution. Prosthetic and in situ grafts are specifically excluded from this report, as well as occluded grafts, found to have stenotic lesions after lytic therapy. The most common stenotic lesion occurred within 4 cm of the proximal anastomosis (29/72 = 40%). The other sites were near the distal anastomosis (7/72 = 10%), and in the middle of the graft (15/72 = 12%). Eighty-one percent (58/72) of the lesions were treated initially by balloon angioplasty with a 31% recurrence. Twenty-nine percent of the 14 grafts treated surgically by vein patch angioplasty or short jump grafts experienced recurrence. Overall 61% (44/72) of the stenotic grafts were treated by balloon angioplasty alone. The 5-year life-table assisted primary patency after correction of the stenotic lesion was 61%. The patency of the grafts from the time of initial bypass surgery, however, was 80%. Location of the stenosis within the graft was a major determinant of patency. Lesions in the proximal graft, proximal anastomosis, and distal graft taken as a group had significantly better patency than the midgraft and distal anastomotic lesions (5-year patency, 65% vs 48%, p less than 0.001 log rank test). We continue to recommend balloon angioplasty as primary therapy for vein graft stenosis except for those occurring in the midgraft and distal anastomosis. Fortunately, this group accounts for only 36% of lesions seen with reversed veins. Recurrent stenosis after balloon angioplasty should be repaired surgically.

Entities:  

Mesh:

Year:  1992        PMID: 1530823     DOI: 10.1067/mva.1992.33492

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

1.  Open surgical revision provides a more durable repair than endovascular treatment for unfavorable vein graft lesions.

Authors:  John C McCallum; Rodney P Bensley; Jeremy D Darling; Allen D Hamdan; Mark C Wyers; Chantel Hile; Raul J Guzman; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2015-10-17       Impact factor: 4.268

2.  Detrimental effects of mechanical stretch on smooth muscle function in saphenous veins.

Authors:  Kyle M Hocking; Colleen Brophy; Syed Z Rizvi; Padmini Komalavilas; Susan Eagle; Marzia Leacche; Jorge M Balaguer; Joyce Cheung-Flynn
Journal:  J Vasc Surg       Date:  2010-12-13       Impact factor: 4.268

3.  Critical Limb Ischemia.

Authors:  David L. Dawson; Ryan T. Hagino
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-06

4.  Immunohistochemical comparison of traditional and modified harvesting of the left internal mammary artery.

Authors:  Mustafa Buyukates; Ozer Kandemir; Banu Dogan Gun; Erol Aktunc; Tolga Kurt
Journal:  Tex Heart Inst J       Date:  2007

5.  Treatment of failing vein grafts in patients who underwent lower extremity arterial bypass.

Authors:  Keun-Myoung Park; Yang Jin Park; Shin-Seok Yang; Dong-Ik Kim; Young-Wook Kim
Journal:  J Korean Surg Soc       Date:  2012-10-29

6.  Effect of different storage solutions on oxidative stress in human saphenous vein grafts.

Authors:  Ilker Tekin; Meltem Demir; Sebahat Özdem
Journal:  J Cardiothorac Surg       Date:  2022-01-16       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.